EZH2 inactivation leads to BCAT1 overactivation, enhancing BCAA metabolism and mTOR signaling, which together drive the transformation of myeloproliferative neoplasms into leukemia (Gu et al., 2019). This evidence concerns the gene EZH2 and leukemia.